BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15145174)

  • 21. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer.
    Kirisits C; Pötter R; Lang S; Dimopoulos J; Wachter-Gerstner N; Georg D
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):901-11. PubMed ID: 15936576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Grading-system-dependent volume effects for late radiation-induced rectal toxicity after curative radiotherapy for prostate cancer.
    van der Laan HP; van den Bergh A; Schilstra C; Vlasman R; Meertens H; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1138-45. PubMed ID: 17931794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy.
    Kouvaris J; Kouloulias V; Malas E; Antypas C; Kokakis J; Michopoulos S; Matsopoulos G; Vlahos L
    Strahlenther Onkol; 2003 Mar; 179(3):167-74. PubMed ID: 12627259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
    Mock U; Bogner J; Georg D; Auberger T; Pötter R
    Strahlenther Onkol; 2005 Jul; 181(7):448-55. PubMed ID: 15995838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101).
    Rancati T; Fiorino C; Gagliardi G; Cattaneo GM; Sanguineti G; Borca VC; Cozzarini C; Fellin G; Foppiano F; Girelli G; Menegotti L; Piazzolla A; Vavassori V; Valdagni R
    Radiother Oncol; 2004 Oct; 73(1):21-32. PubMed ID: 15465142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosimetric factors predicting severe radiation-induced bowel complications in patients with cervical cancer: combined effect of external parametrial dose and cumulative rectal dose.
    Huang EY; Wang CJ; Hsu HC; Hao Lin ; Chen HC; Sun LM
    Gynecol Oncol; 2004 Oct; 95(1):101-8. PubMed ID: 15385117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
    Leborgne F; Fowler J
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri.
    Onsrud M; Hagen B; Strickert T
    Gynecol Oncol; 2001 Jul; 82(1):167-71. PubMed ID: 11426980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoxic versus normoxic external-beam irradiation of cervical carcinoma combined with californium-252 neutron brachytherapy. Comparative treatment results of a 5-year randomized study.
    Tacev T; Vacek A; Ptácková B; Strnad V
    Strahlenther Onkol; 2005 May; 181(5):273-84. PubMed ID: 15900423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
    O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
    Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
    Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
    Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies.
    Georg P; Georg D; Hillbrand M; Kirisits C; Pötter R
    Radiother Oncol; 2006 Jul; 80(1):19-26. PubMed ID: 16766068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.